9 May 2023 - - US-based biopharmaceutical company Incyte (NASDAQ: INCY) has created a new leadership role, appointing Pablo J. Cagnoni, M.D. president and Head of Research & Development effective June 5, 2023, the company said.

In this role and as a member of the Executive Team, Dr. Cagnoni will lead Incyte's R&D efforts across its portfolio of programs in Oncology, Hematology and Inflammation and Autoimmunity including Dermatology.

As an oncologist and pharmaceutical executive, Dr. Cagnoni has advanced the development of breakthrough treatments throughout his career playing a key role in the development, approval and/or commercialization of more than 20 life-changing medicines.

Pablo most recently served as chief executive officer of Laronde, a company dedicated to the development of a new type of translatable ribonucleic acid, endless RNA.

Previously he was president and chief executive officer of Rubius Therapeutics, a biopharmaceutical company focused on cellular therapies for the treatment of cancer and autoimmune diseases.

Before joining Rubius he was chief executive officer of Tizona Therapeutics, a privately held biotech company focused on developing immunotherapies for the treatment of cancer.

He joined Tizona as the company's first employee and grew the organization to support the filing of its first Investigational New Drug application. In 2020, Gilead Sciences secured an exclusive option to acquire Tizona for up to USD 1.5bn.

Prior to Tizona, Dr. Cagnoni was president of Onyx Pharmaceuticals which was acquired by Amgen.

There he had global strategic oversight and accountability of the Onyx portfolio from early product development to commercialization. Previously he served as Global Head of Clinical Development at Novartis Oncology.

Dr. Cagnoni received his Doctor of Medicine from the University of Buenos Aires School of Medicine and completed fellowships in Hematology and Oncology at the Mount Sinai Medical Center in New York, and in Stem Cell Transplantation at the University of Colorado Health Sciences Center.

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.